Patents
Literature
6 results about "Guanylate cyclase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Guanylate cyclase (EC 4.6.1.2, also known as guanyl cyclase, guanylyl cyclase, or GC) is a lyase enzyme. Guanylate cyclase is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylate cyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. Like cAMP, cGMP is an important second messenger that internalizes the message carried by intercellular messengers such as peptide hormones and nitric oxide, and can also function as an autocrine signal. Depending on cell type, it can drive adaptive/developmental changes requiring protein synthesis. In smooth muscle, cGMP is the signal for relaxation, and is coupled to many homeostatic mechanisms including regulation of vasodilation, vocal tone, insulin secretion, and peristalsis. Once formed, cGMP can be degraded by phosphodiesterases, which themselves are under different forms of regulation, depending on the tissue.
Genetically engineered bacteria for synthesizing natural cyclic diguanosine monophosphate in large quantities and application thereof
ActiveCN117701596BPhosphodiesteraseCyclase
This invention discloses a genetically engineered bacterium capable of synthesizing large quantities of natural cyclic diguanylate (c-di-GMP) and its applications. It involves knocking out the major phosphodiesterase gene chr1_233 as described in claim 1 within the sphingobium xenophagum C2 strain. This invention rationally designs and modifies the c-di-GMP synthesis and degradation pathways and the inhibitory site of major diguanylate cyclase activity in heterologous sphingobium-consuming bacteria, constructing a series of genetically engineered bacteria capable of synthesizing large quantities of natural c-di-GMP. This provides the industry with a green, simple, economical, and efficient method for producing natural c-di-GMP, and offers a series of high-quality and inexpensive raw materials for the preparation of STING agonists or immune adjuvants, or for the preparation of drugs for treating diseases related to STING protein function.
Owner:GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY
Guanylate cyclase-c activator peptide and uses thereof
This invention discloses a guanylate cyclase-C (GC-C) activating peptide and its applications, belonging to the field of bioactive peptide technology. The amino acid sequence of the GC-C activating peptide is PFPGPIPN. The GC-C activating peptide of this invention can significantly activate GC-C activity, increasing intracellular cGMP levels. Furthermore, the GC-C activating peptide of this invention can alleviate constipation and abdominal pain symptoms in mice, thereby effectively preventing or improving irritable bowel syndrome (IBS). Therefore, the GC-C activating peptide provided by this invention has advantages such as high activity, safety and non-toxicity, and good water solubility. It can be used as a candidate molecule for alternative or adjuvant drugs in the clinical treatment of IBS, and also as a health product or food to improve constipation or abdominal pain.
Owner:NORTHWEST A & F UNIV +1
TREATMENT OF MITOCHONDRIAL DISEASES WITH sGC STIMULATORS
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various mitochondrial diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO-sGC-cGMP pathway is desirable. Compounds useful in the methods of the invention are those of Formula I or pharmaceutically acceptable salts thereof.
Owner:TISENTO THERAPEUTICS INC
RAAV-GUANYLATE CYCLASE COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBER'S CONGENITAL AMAUROSE-1 (LCA1)
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC
Heterocyclic carboxylic acid derivative, preparation method therefor, and pharmaceutical application thereof
Provided are a heterocyclic carboxylic acid derivative, a preparation method therefor, and a pharmaceutical application thereof. Specifically, provided are a heterocyclic carboxylic acid derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as an sGC (soluble guanylate cyclase) agonist and / or activator, and the use thereof in the preparation of a drug for treating and / or preventing diseases responsive to sGC agonists and / or activators.
Owner:SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD
Pyrimidine sgc stimulators
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an uregulation of the NO pathway is desirable. In some embodiments, the compounds are those of Formula I or a pharmaceutically acceptable salt thereof. (I)
Owner:TISENTO THERAPEUTICS INC